PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20128812-6	2010	Further, the selective 5-HT reuptake inhibitor fluvoxamine increased WAY 100635 induced head twitches in SERT +/+ and +/- mice.	Fluvoxamine	47-58	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	105-109	
16079297-9	2005	Furthermore, the time-dependent change of SERT mRNA expression and uptake activity in the midbrain is suggested to be the mechanism underlying the 24-h rhythm of anti-immobility effect of fluvoxamine.	Fluvoxamine	188-199	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	42-46	
18655786-13	2008	Furthermore, differences in 5-HT transporter binding may cause variations in responses to fluvoxamine.	Fluvoxamine	90-101	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	28-44	
15678084-3	2005	Oral administration of fluvoxamine, fluoxetine, paroxetine and sertraline at pharmacologically relevant doses exerted dose- and time-dependent binding activity of brain SERT as revealed by significant increases in KD for specific [3H]paroxetine binding, and the in vivo SERT-binding potency was in the order of paroxetine>>fluoxetine, sertraline>fluvoxamine.	Fluvoxamine	23-34	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	169-173	
15678084-3	2005	Oral administration of fluvoxamine, fluoxetine, paroxetine and sertraline at pharmacologically relevant doses exerted dose- and time-dependent binding activity of brain SERT as revealed by significant increases in KD for specific [3H]paroxetine binding, and the in vivo SERT-binding potency was in the order of paroxetine>>fluoxetine, sertraline>fluvoxamine.	Fluvoxamine	23-34	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	270-274	
15678084-3	2005	Oral administration of fluvoxamine, fluoxetine, paroxetine and sertraline at pharmacologically relevant doses exerted dose- and time-dependent binding activity of brain SERT as revealed by significant increases in KD for specific [3H]paroxetine binding, and the in vivo SERT-binding potency was in the order of paroxetine>>fluoxetine, sertraline>fluvoxamine.	Fluvoxamine	355-366	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	169-173	
15678084-11	2005	In conclusion, the present study has provided the first in vivo evidences to support that fluvoxamine, fluoxetine, paroxetine and sertraline orally administered bind to the pharmacologically relevant brain SERT in mice and that their SERT-binding characteristics is closely associated with the pharmacokinetics and inhibition of marble-burying behaviour.	Fluvoxamine	90-101	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	206-210	
15678084-11	2005	In conclusion, the present study has provided the first in vivo evidences to support that fluvoxamine, fluoxetine, paroxetine and sertraline orally administered bind to the pharmacologically relevant brain SERT in mice and that their SERT-binding characteristics is closely associated with the pharmacokinetics and inhibition of marble-burying behaviour.	Fluvoxamine	90-101	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	234-238	
14501158-4	2003	The compound was as effective as SERT inhibitors such as fluoxetine and fluvoxamine in a 5-hydroxytryptophan-enhancing test in mice.	Fluvoxamine	72-83	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4	Mus musculus	33-37